{"id":"NCT00703937","sponsor":"American Regent, Inc.","briefTitle":"Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia","officialTitle":"A Multi-center, Randomized, Controlled Study to Investigate the Safety and Tolerability of Intravenous Ferric Carboxymaltose (FCM) vs. Standard Medical Care in Treating Iron Deficiency Anemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-07","primaryCompletion":"2009-07","completion":"2011-03","firstPosted":"2008-06-24","resultsPosted":"2013-11-25","lastUpdate":"2018-02-20"},"enrollment":708,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Anemia"],"interventions":[{"type":"DRUG","name":"Ferric Carboxymaltose (FCM)","otherNames":[]},{"type":"DRUG","name":"Standard Medical Care (SMC) for the treatment of IDA","otherNames":[]}],"arms":[{"label":"Ferric Carboxymaltose (FCM)","type":"EXPERIMENTAL"},{"label":"Standard Medical Care (SMC) for the treatment of IDA","type":"ACTIVE_COMPARATOR"}],"summary":"The objective of this study is to evaluate the safety of FCM in patients with anemia who are not dialysis dependent.","primaryOutcome":{"measure":"Safety, as Defined by the Occurence of Serious Adverse Events (SAE's), of FCM Compared to SMC","timeFrame":"First administration of FCM, or Day 0 for SMC subjects, through end of study (Day 42) or 28 days after the last dose of study drug (FCM or SMC) whichever was longer","effectByArm":[{"arm":"Ferric Carboxymaltose (FCM)","deltaMin":17,"sd":null},{"arm":"Standard Medical Care (SMC) for the Treatment of IDA","deltaMin":11,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":9},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":343},"commonTop":["Nausea","Constipation","Headache"]}}